about
Mapping and structural dissection of human 20 S proteasome using proteomic approachesPromotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy geneMG-132, an inhibitor of proteasomes and calpains, induced inhibition of oocyte maturation and aneuploidy in mouse oocytesProteasome inhibitors in progressive renal diseasesIdentification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombeRole of the ubiquitin system and tumor viruses in AIDS-related cancer.A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapyInhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosisCombination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.Role of CXCL1 in tumorigenesis of melanoma.Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies.Future potential of thymidylate synthase inhibitors in cancer therapy.Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care.Bone marrow transplant in Ph+ ALL patients.Proteasome inhibition: a new anti-inflammatory strategy.Proteasome Inhibitor Bortezomib Enhances the Activity of Multiple Mutant Forms of Lysosomal α-Glucosidase in Pompe DiseaseEPMA position paper in cancer: current overview and future perspectives.Regulation of nicotinic acetylcholine receptor assembly.Novel therapies for patients with chronic myeloid leukemia.Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.A review of the proteasome inhibitor bortezomib in multiple myeloma.Proteasome inhibition in hematologic malignancies.The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy.TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Advances in the treatment for haematological malignancies.A novel proteasome inhibitor NPI-0052 as an anticancer therapy.Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors.Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.Bortezomib reduces neointimal hyperplasia in a rat carotid artery injury model.NF-kappaB regulates androgen receptor expression and prostate cancer growth.The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity.First insight into the proteome landscape of the porcine short posterior ciliary arteries: Key signalling pathways maintaining physiologic functions.Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.Controlling subcellular delivery to optimize therapeutic effectThe novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis.Therapeutic targeting of cancer cell cycle using proteasome inhibitors
P2860
Q24310815-6A1CADBD-859E-4702-990B-5118707FBB60Q24617547-1ED514ED-F0A1-413C-9D2F-64EE219C73E1Q24798812-B504A682-81C1-4837-ACF0-AE036EF1E5ECQ27011485-440C3B52-D96E-4C61-B3CE-C24CC3AC0DC1Q28478963-B9080792-2BFF-4EC4-99F1-A9D72999EA38Q33307881-E03193A7-4981-47CF-838B-FE328B89B5A2Q33380300-3FA88C11-C404-4204-96F8-23EED0A886A1Q33754991-73A70E23-B80C-4FDC-8E67-8C17481E6C10Q34198852-A85CA45A-0C07-4268-B261-FDD7CD243B97Q34313670-B20A15DC-A4A0-41CE-BA6A-46E1F05B71B7Q34665595-F7CBBEE3-ADA5-46EF-8513-4F792C8B5F4AQ34724089-8B0EFB73-04C5-47A7-A535-C2A4EAECE106Q34929081-B91F6199-E819-4D0F-86D5-814207D569CAQ35011904-876D4416-8F98-4CAB-BE83-7888592BFA43Q35016589-3EF9B88E-9022-4CD2-833D-84C59DF1AADBQ35106125-A105B1CA-1379-4388-88DF-FA71ABF6AB67Q35109750-5DA3400C-5951-4133-8D7B-DFD055874894Q35183088-4B48A22F-8CFE-4616-8E90-8D547A038559Q35532215-4131ADC6-CAAD-422D-A51D-0F283EE891ADQ35573354-E3A84444-480E-41B5-A38E-24A1B51F870DQ35728742-E0EBD60C-05D8-47EA-B542-9B4F7C00BEE4Q35759168-FD0FDF4D-9BB9-494B-8A01-D099BEE1DE76Q35784057-94C91FF3-9213-49F9-8538-C668A3B801B7Q35821602-B70CB977-8F6B-4AFA-9B03-92CB4187A689Q36066214-1FE23051-8B75-46DE-85BD-B9F76C0092D6Q36365504-16739049-A28E-46A2-A344-06D81422578BQ36429723-A6B8B710-5147-4CDF-95CE-8F65CB338B1CQ36626591-7E65F6D2-03CB-4F25-A385-146FB1D5CD5EQ36893329-33835297-ABFC-453F-9B01-7AAA61902D39Q36915734-09FD6E52-E14E-492F-A791-C39DA508D3C5Q37074133-02C2332D-7407-4C7A-847E-B79BA1CE1464Q37129891-F61512B6-E83D-411C-9566-7EC14706625AQ37256678-D27D5DCA-AAE8-4EE3-B79B-A237EF4A74B3Q37278416-796DC17F-79DE-4E02-AF6A-C773351ABAB3Q37392803-DBB286D1-420E-4188-91A3-8E20DEB8E2B7Q37476133-159483BA-C31E-42F4-A630-201A2E63662FQ37677121-8A76D91C-6186-4166-A1E0-F39DDF6C527EQ37813021-EAF746E5-ECDE-4FF8-BA36-3CA224027FDAQ38061412-9EAF61FB-BD8E-47E3-807C-601C94EE5064Q38069898-25AD56BA-C0F9-40A1-92D7-92EE751A4CE5
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The proteasome: a new target for novel drug therapies.
@ast
The proteasome: a new target for novel drug therapies.
@en
The proteasome: a new target for novel drug therapies.
@nl
type
label
The proteasome: a new target for novel drug therapies.
@ast
The proteasome: a new target for novel drug therapies.
@en
The proteasome: a new target for novel drug therapies.
@nl
prefLabel
The proteasome: a new target for novel drug therapies.
@ast
The proteasome: a new target for novel drug therapies.
@en
The proteasome: a new target for novel drug therapies.
@nl
P1476
The proteasome: a new target for novel drug therapies.
@en
P2093
P304
P356
10.1309/44HW-5YCJ-FLLP-3R56
P407
P577
2001-11-01T00:00:00Z